CME/CE

This 15-minute audio podcast uses real-world patient cases to illustrate effective strategies for managing adverse events (AEs) associated with GPRC5D-directed therapies in multiple myeloma. Expert faculty discuss how to safely implement these therapies to achieve deep, durable responses while optimizing patient tolerability and quality of life. Listeners will gain insights into specific prophylaxis, dosing, and interprofessional management protocols to address unique AEs such as cytokine release syndrome, skin toxicity, and dysgeusia. This practical case-based discussion will equip healthcare professionals with actionable tools to improve outcomes for their patients with relapsed/refractory multiple myeloma.

Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.

Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.

Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.

This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.

Complete both modules, answer pre- and post-test questions and start earning CME credits.

This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.

This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.

Complete both modules, answer pre- and post-test questions and start earning CME credits.

This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.

Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.

Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.

Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.

Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.